Pros

MeiraGTx Reports First Quarter 2024 Financial and Operational Results

Retrieved on: 
星期四, 五月 9, 2024
FDA, Research, UCL Business, Weight loss, IND, Oxyntomodulin, Visual acuity, RIX, Oral medicine, American Academy, Brain, STN, Facial muscles, Technology transfer, Janssen Pharmaceuticals, Appetite, BLA, MHRA, Messenger, Subthalamic nucleus, Safety, Diabetes, Insurance, RNA, AAOM, AAV, Dopamine, Obesity, DNA, Autoimmune disease, Motor cortex, Treatment, Pros, GMP, GIP, Clinical trial, File, PSMA, Sale, Radiation, Neurodegenerative disease, DSM-IV codes, Saliva, Health care, Xerostomia, Patient, Riboswitch, Gene, Peptide, Head, PYY, Pharmaceutical industry

LONDON and NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • MeiraGTx anticipates receiving an additional $15 million in near-term milestone payments later in 2024.
  • As of March 31, 2024, MeiraGTx had cash and cash equivalents of approximately $119.2 million and in April 2024, the Company collected $19.7 million in receivables which were due in the first quarter of 2024, effectively increasing the cash balance to $138.9 million.
  • The increase of $0.6 million was due to higher interest rates and cash balances during 2024.
  • Interest expense was $3.3 million for the three months ended March 31, 2024, compared to $3.1 million for the three months ended March 31, 2023.

Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights

Retrieved on: 
星期二, 五月 7, 2024
Doctor of Philosophy, Research and development, Stroke, Kidney disease, Investment, Plan, Research, Cohort, Life, Administration, Disease, Therapy, Incidence, Patient, Calciphylaxis, Pros, Cardiovascular disease, Interim, DSM-IV codes, G&A

BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the first quarter ended March 31, 2024, and provided business highlights.

Key Points: 
  • In April 2024, the Company announced positive topline safety and immunogenicity data, with clinical improvements in vascular pathology, visual function, and patient reported outcomes (PROs).
  • R&D expenses were $19.1 million for the quarter ended March 31, 2024, compared to $11.9 million for the prior-year period.
  • G&A expenses were $5.2 million for the quarter ended March 31, 2024, compared to $6.5 million for the prior-year period.
  • Net loss was $23.3 million, or $0.38 loss per share, for the quarter ended March 31, 2024, compared to $17.4 million or $0.40 loss per share for the prior-year period.

A Holistic Approach to Parkinson's Disease Endpoint Data Collection: Efficacy, Safety and Quality of Life, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
星期二, 四月 30, 2024
Brain, Parkinson's disease, Safety, QOL, Data science, MD, Doctor of Philosophy, American Opportunity Tax Credit, Diary, QT, Pros, MPH, Medicine, PD, Quality of life, Dysautonomia

TORONTO, April 30, 2024 /PRNewswire-PRWeb/ -- In this webinar, the expert speakers will comprehensively explore Parkinson's disease endpoint data collection, where they will delve into the crucial elements of efficacy, safety and quality of life. The webinar will highlight the revolutionary Opal wearable solution and its important role in providing quantitative gait assessments, thus offering a better understanding of disease progression.

Key Points: 
  • TORONTO, April 30, 2024 /PRNewswire-PRWeb/ -- In this webinar, the expert speakers will comprehensively explore Parkinson's disease endpoint data collection, where they will delve into the crucial elements of efficacy, safety and quality of life.
  • The webinar will highlight the revolutionary Opal wearable solution and its important role in providing quantitative gait assessments, thus offering a better understanding of disease progression.
  • These circuits represent crucial targets for assessing patient eligibility, safety and therapeutic efficacy in the development of disease-modifying therapies.
  • Register for this webinar to learn about the complexities of Parkinson's disease endpoint data collection and obtain invaluable insights for improving patient outcomes and advancing therapeutic interventions.

Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting

Retrieved on: 
星期一, 四月 29, 2024
Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, PFS, Brentuximab vedotin, Triple-negative breast cancer, Lung cancer, MBC, ASCO, Lymphoma, PFE, Metastasis, ALK, Breast cancer, Learning, CRS, Food, Colorectal cancer, Abstract, RRMM, Rituximab, ADC, HR, CDK4, De novo, Spacecraft, DLBCL, Tucatinib, Anaplastic lymphoma kinase, Safety, Crizotinib, Pembrolizumab, Survival, EZH2, Pros, Inc., Neoplasm, Progression-free survival, Recurrence, PAL, Biologics license application, HRR, Hodgkin lymphoma, Patient, Society, Cyclin-dependent kinase 4, Cytokine release syndrome, Annual general meeting, APLS, PBC, Lenalidomide, B-cell lymphoma, Pharmaceutical industry

Pfizer Inc. (NYSE: PFE) highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 31 to June 4 in Chicago.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 31 to June 4 in Chicago.
  • “We are excited to participate in our first ASCO Annual Meeting following the creation of Pfizer’s new Oncology organization, where we will highlight our efforts to accelerate breakthrough medicines that help people with cancer live better and longer lives,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer.
  • An oral presentation on extended duration of response from the Phase 3 MOUNTAINEER trial adds to the positive profile of TUKYSA in colorectal cancer.
  • Those interested in learning more can visit www.Pfizer.com/apls to access the summaries starting Friday, May 24.

Bardavon Sets a New Standard for Workers’ Compensation with Launch of Recovery+

Retrieved on: 
星期二, 四月 30, 2024
Technology, Labor, Fitness & Nutrition, Health Technology, Public Policy, Government, Software, Networks, Other Health, General Health, Health, Pain, Cox Enterprises, Recovery, Fear, Risk, Research, Risk management, Conference, Person-centered therapy, MSK, Pros, Anxiety, Nursing

Bardavon , a leading workers’ compensation and musculoskeletal (MSK) health company, announced today the launch of Recovery+ , an industry-leading health coaching platform designed to expedite recovery and enhance the return-to-work process for injured workers.

Key Points: 
  • Bardavon , a leading workers’ compensation and musculoskeletal (MSK) health company, announced today the launch of Recovery+ , an industry-leading health coaching platform designed to expedite recovery and enhance the return-to-work process for injured workers.
  • Recovery+ is now part of Bardavon's PT/OT network offering , actively being adopted by existing clients and available for new clients.
  • Through the Recovery+ program, injured workers receive personalized text messages from a dedicated Recovery Coach assessing patient-reported outcomes (PROs) and delivering workers’ compensation and injury-specific education.
  • This helps identify biopsychosocial factors such as pain, movement dysfunction, fear, and anxiety, enabling Recovery Coaches to offer tailored support.

Volley's AI-Enabled Racquet Simulator Helps Racquet Sports Pros Boost Income, According to New Survey

Retrieved on: 
星期三, 四月 24, 2024
AI, Pros, Simulation, Tennis

CHICAGO and LANCASTER, Pa., April 24, 2024 /PRNewswire-PRWeb/ -- Today, Volley, innovator of the first AI-enabled racquet sports simulator experience, is sharing new insights from a recent survey of padel and platform tennis Pros who are using the Volley Simulator to benchmark its impact on the coaching landscape. Amongst the findings, 100% of Pros reported that their income was the same or higher after the introduction of Volley to their program, while 35% have seen an increase in income.

Key Points: 
  • We are partners to the leaders in the field and want to help foster that collaboration through our Simulator."
  • The Volley Simulator uses AI technology to analyze player performance and provide personalized feedback, allowing Pros to tailor their coaching approach to individual needs.
  • "Because of Volley, I didn't have to cancel my lessons, and I used the Simulator to feed shots and analyze player performance.
  • To learn more about how Volley supports Pros, programs, and players, visit https://getvolley.com/pros .

TuneCore Expands Music Publishing Services and User Experience to Aid Independent Songwriters

Retrieved on: 
星期二, 四月 23, 2024
Sentric Music, Pros, Publishing, TuneCore, Spotify, Music

NEW YORK, April 23, 2024 /PRNewswire-PRWeb/ -- TuneCore, the leading independent development partner for self-releasing artists—owned by Believe, one of the world's leading digital music companies—has rolled out a comprehensive suite of music publishing services to help independent songwriters increase their earnings in over 200 countries.

Key Points: 
  • Andreea Gleeson, Chief Executive Officer, TuneCore commented, "TuneCore Publishing now offers songwriters even more flexibility and control over their publishing revenue while also providing key analytical insights to help our songwriters grow their careers.
  • TuneCore's newly expanded music publishing services arrive at no increased cost for TuneCore artists, with TuneCore Publishing continuing to allow songwriters to submit unlimited songs for a one-time $75 set-up fee and a competitive 15% commission.
  • TuneCore has also significantly enhanced the TuneCore Publishing interface, giving songwriters the ability to submit multiple recordings of their compositions directly from their dashboard, improving user experience, and allowing songwriters to more easily maximize their publishing earnings.
  • Through expanded services, faster payments, and increased transparency into the complex world of music publishing, TuneCore has established itself as one of the leading providers of music publishing services on behalf of self-releasing artists, giving them the greatest opportunity to earn money from their music and build sustainable careers.

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

Retrieved on: 
星期一, 四月 8, 2024
Patient, Cerebrovascular disease, Stroke, Accelerated approval (FDA), European Medicines Agency, Doctor of Philosophy, Osteomalacia, PROMIS, Therapy, Conditional, Natural history, CTX, Pros, ADAS, Risk, DSM-IV codes, Cohort, Aes, Alkaline phosphatase, Rickets, EMA, PXE, Safety, Epilepsy, Clinical trial, Food, Hospital, Disability, BSAP, Cardiovascular disease, Disease, PD, Paresis, Consultant, Hypophosphatemia, Fatigue, Survivor, Sclera, FDA, Observational study, Pyrophosphate, Choroid, Incidence, Retina, Biomarker, Life, Event, Medical imaging

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced positive topline safety, pharmacokinetic (PK), pharmacodynamic (PD) and exploratory efficacy data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ABCC6 Deficiency (PXE, pseudoxanthoma elasticum) and ENPP1 Deficiency.

Key Points: 
  • “We are excited by the excellent safety and preliminary efficacy profile of INZ-701 in adults with ABCC6 Deficiency,” said Douglas A. Treco, Ph.D., CEO of Inozyme Pharma.
  • The patients were assigned to three dose cohorts of INZ-701: 0.2 mg/kg (n=3), 0.6 mg/kg (n=3), and 1.8 mg/kg (n=4).
  • For trial design details, please see the section entitled “INZ-701 in ABCC6 Deficiency Phase 1/2 Clinical Trial Design” below.
  • For trial design details, please see the section entitled “INZ-701 in ENPP1 Deficiency Phase 1/2 Clinical Trial Design” below.

YPrime Survey Reveals Challenges and Opportunities for Streamlining Oncology Trials with eCOA

Retrieved on: 
星期三, 四月 3, 2024
Risk, American Opportunity Tax Credit, Pros, Patient, Uncertainty, Burden, Pressure, Data collection, Clinical trial, Medical imaging

The report detailing and analyzing the findings, Decreasing the Burden of Oncology Clinical Trials with eCOA , sheds light on the specific challenges and opportunities surrounding electronic clinical outcome assessment (eCOA) use in oncology trials.

Key Points: 
  • The report detailing and analyzing the findings, Decreasing the Burden of Oncology Clinical Trials with eCOA , sheds light on the specific challenges and opportunities surrounding electronic clinical outcome assessment (eCOA) use in oncology trials.
  • While all clinical trials share similarities, oncology trials present distinct complexities.
  • "By improving patient engagement, streamlining data collection, and enabling real-time insights, eCOA platforms can significantly reduce risk and uncertainty in oncology trials.
  • For a complete analysis of the survey findings and a deeper dive into how eCOA can optimize your oncology trials, download the complimentary report, Decreasing the Burden of Oncology Clinical Trials with eCOA .

Canada Plastics Pact Surpasses 100 Partners, Welcomes Six New Partners To Tackle Plastic Waste and Pollution

Retrieved on: 
星期二, 四月 2, 2024
Partner, EPR, Pros, Environment, Recycling, Interchange, Extended producer responsibility, Polymer, Education, Research, Policy, Food, Private sector, Wind, CPP, Personal protective equipment, Plastic, Collection, Movement, PPE

Denovia Labs is a research company working to reshape plastic waste management.

Key Points: 
  • Denovia Labs is a research company working to reshape plastic waste management.
  • They have developed a proprietary innovative approach to transform various forms of plastic waste back to its base chemical building blocks.
  • Ocean Legacy Foundation is a Canadian-based non-profit organization that develops and implements worldwide plastic pollution response programs, with the goal to end plastic pollution.
  • This guidance was developed by a cross-section of CPP Partners to be used by all Canadian stakeholders that put plastics in the market.